… the selective pressure exerted by each targeted therapy. In some (but not all) cases, the
evolution of TKI resistance can lead to significant tumor heterogeneity within a given cancer. …

… Targeted therapy has emerged as an … cell lung cancer (NSCLC). Herein, we review and
analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer…

… of individualized therapy. In this article we review clinical data for molecular-targeted therapies
in … Nonetheless, for most patients with NSCLC targeted therapies have not dramatically …

… This design of clinical trials of testing the efficacy of targeted therapies … targeted therapy
trials in lung cancer with other actionable oncogenic drivers. Molecular profiling of lung cancers …

… This review focuses on the targeted therapies in lung cancer: the molecular biomarkers that
… from these targeted therapies, the basic molecular biology principles behind these therapies, …

… Perhaps the best example of how biomarker-driven targeted therapy has shifted the paradigm
of lung cancer treatment is the management of EGFR-mutant NSCLC. Activating mutations …

… shift in the management of non-small cell lung cancer (NSCLC). NSCLC should now be …
without a known driver mutation, targeted therapy is pushing the boundary to significantly …

… effective targeted therapies in metastatic NSCLC. Currently, five molecular targeted agents
… This review will focus on the rationale for the development of targeted therapies in NSCLC …

… Since 1998, when trastuzumab was the first molecularly targeted drug approved by US …
cancers until the end of 2009. However, the clinical response obtained from targeted therapies is …

… targeting EGFR family members, novel EML4-ALK inhibitors and MEK inhibitors are currently
in clinical development. Availability of targeted therapies … in use of targeted therapy, with a …